<p>纽约，NY / ACCESS Newswire /2025 年 10 月 27 日/ 如果您在 <strong>Baxter International, Inc.</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
<p>https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24</p>
<p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。</p>
<p><strong>诉讼：</strong> 针对 Baxter International, Inc.提起了一项集体诉讼，旨在追回在 2022 年 2 月 23 日至 2025 年 7 月 30 日期间因涉嫌证券欺诈而受到不利影响的股东损失。</p>
<p><strong>案件详情：</strong> 提交的投诉指控被告发表虚假陈述和/或隐瞒了以下事实：(a) Baxter 最近推出的产品 Novum LVP 存在系统性缺陷，导致广泛的故障，包括输液不足、输液过量和完全不输液，给患者带来了严重伤害或死亡的风险；(b) Baxter 已被通知多起设备故障、伤害和因这些缺陷导致的死亡；(c) Baxter 通过客户警报来解决这些缺陷的尝试是不充分的补救措施，因为设计缺陷仍然存在并继续对患者造成严重伤害；(d) 因此，客户被指示将现有的 Novum LVP 停用的风险增加，Baxter 将完全暂停所有新销售这些泵的可能性；(e) 基于上述情况，Baxter 关于 Novum LVP 的安全性、有效性、产品推出、客户反馈和销售前景的陈述是实质性虚假和误导的。</p>
<p><strong>接下来怎么办？</strong> 如果您在相关时间段内在 Baxter International, Inc.的股票中遭受损失——即使您仍持有股份——请访问 https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24 了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
<p><strong>为什么选择 LEVI &amp; KORSINSKY：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼方面拥有丰富的专业知识，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 报告中被评为美国顶级证券诉讼公司之一。律师广告。以往的结果并不保证类似的结果。</p>
<p><strong>联系方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 27th Floor</p>
<p>纽约，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>电话：(212) 363-7500</p>
<p>传真：(212) 363-7171</p>
<p>https://zlk.com/</p>
<p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

<p>针对百特国际公司（Baxter International, Inc.，股票代码：BAX）提起了一项集体诉讼，指控其在 2022 年 2 月 23 日至 2025 年 7 月 30 日期间存在证券欺诈行为。诉状称，百特的 Novum LVP 产品存在系统性缺陷，导致严重的患者风险，并且公司关于该产品安全性和有效性的声明具有误导性。遭受损失的股东被鼓励联系 Levi & Korsinsky LLP，以寻求潜在的赔偿选项</p>

<p>NEW YORK, NY / ACCESS Newswire / October 27, 2025 / If you suffered a loss on your <strong>Baxter International, Inc.</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p>纽约，NY / ACCESS Newswire /2025 年 10 月 27 日/ 如果您在 <strong>Baxter International, Inc.</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
</div><p>https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against Baxter International, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025.</p>
<div class="lb-trans"><p><strong>诉讼：</strong> 针对 Baxter International, Inc.提起了一项集体诉讼，旨在追回在 2022 年 2 月 23 日至 2025 年 7 月 30 日期间因涉嫌证券欺诈而受到不利影响的股东损失。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (a) Baxter's recently launched product, the Novum LVP, suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (b) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (c) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (d) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (e) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading.</p>
<div class="lb-trans"><p><strong>案件详情：</strong> 提交的投诉指控被告发表虚假陈述和/或隐瞒了以下事实：(a) Baxter 最近推出的产品 Novum LVP 存在系统性缺陷，导致广泛的故障，包括输液不足、输液过量和完全不输液，给患者带来了严重伤害或死亡的风险；(b) Baxter 已被通知多起设备故障、伤害和因这些缺陷导致的死亡；(c) Baxter 通过客户警报来解决这些缺陷的尝试是不充分的补救措施，因为设计缺陷仍然存在并继续对患者造成严重伤害；(d) 因此，客户被指示将现有的 Novum LVP 停用的风险增加，Baxter 将完全暂停所有新销售这些泵的可能性；(e) 基于上述情况，Baxter 关于 Novum LVP 的安全性、有效性、产品推出、客户反馈和销售前景的陈述是实质性虚假和误导的。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in Baxter International, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下来怎么办？</strong> 如果您在相关时间段内在 Baxter International, Inc.的股票中遭受损失——即使您仍持有股份——请访问 https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=174065&amp;wire=1&amp;utm_campaign=24 了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>为什么选择 LEVI &amp; KORSINSKY：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中赢得了良好的记录。该公司在复杂证券诉讼方面拥有丰富的专业知识，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 报告中被评为美国顶级证券诉讼公司之一。律师广告。以往的结果并不保证类似的结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 27th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 27th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>纽约，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>电话：(212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>传真：(212) 363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

追回投资损失：已对 Baxter International, Inc.（BAX）发起集体诉讼